
Anthropic’s Drug Discovery Dreams: ‘It Is Not A Side Effort’
By Amy Feldman, Forbes Staff
Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.
This story was published by Forbes. Read the full article on their site.
Read the full story at forbes.com(opens in a new tab)





